DPP4 and Stroke: Dipeptidyl peptidase 4 inhibitors did not significantly increase the risk of stroke compared with controls (OR= 1.01; 95% CI, 0.78–1.30; Figure 6), and there was no heterogeneity (I2 = 39.8%, P = 0.056).